These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 16998938)

  • 21. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia.
    Rozen P; Knaani J; Samuel Z
    Dig Dis Sci; 1997 Oct; 42(10):2064-71. PubMed ID: 9365136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance improvements of stool-based screening tests.
    van Dam L; Kuipers EJ; van Leerdam ME
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
    Berchi C; Guittet L; Bouvier V; Launoy G
    Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.